New radioactive treatment for advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with thyroid cancer, and if it's the common type, it should no longer respond to radioactive iodine therapy.
- Your cancer must be growing or spreading based on recent scans (CT or MRI).
- You must have had at least one prior targeted therapy (like pills or IV treatment) that didn't work, caused side effects, or you chose not to continue.
- A special PET scan (called FAPI PET) must show that more than half of your cancer spots are very active (bright).
- You must have at least one tumor that can be measured on a scan (about the size of a grape or larger).
- You must be generally well enough to perform daily activities (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
This trial tests a new type of PET scan (F-18 Tetrafluoroborate) to find thyroid cancer cells that don't show up on standard scans. It's for people who have had surgery and radioactive iodine therapy but still have signs of cancer in their blood tests.
This study uses a special type of PET/CT scan (68Ga-FAPI) to see how well it finds cancer spread in lymph nodes before thyroid cancer surgery. It may help doctors plan your treatment more accurately.
This study tests a new type of PET scan to find thyroid cancer that has come back or spread. It compares two tracers to see which one better shows the cancer, which may help doctors choose the right treatment.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.